ChengDu Sheng Nuo Biotec (688117.SH): Approval of the application for listing of the raw material drug Vapenapeptide.

Chengdu Shengnuo Biotech (688117.SH) announced that its wholly-owned subsidiary, Chengdu Shengnuo Biotech Pharmaceutical Co., Ltd., recently received the "Chemical Active Pharmaceutical Ingredients Market Approval Notice" from the National Medical Products Administration (hereinafter referred to as the "NMPA") for the active pharmaceutical ingredient of semaglutide. Semaglutide is a PEGylated analog of liraglutide that combines and activates the GLP-1 receptor in the body as a GLP-1 receptor agonist. It has similar physiological effects to native human GLP-1, enhancing insulin secretion and lowering blood sugar levels in a glucose-dependent manner, thus treating type 2 diabetes and obesity.